Teleflex Incorporated (NYSE:TFX - Free Report) - Investment analysts at Zacks Research cut their Q2 2025 earnings per share (EPS) estimates for shares of Teleflex in a report issued on Tuesday, June 24th. Zacks Research analyst R. Department now expects that the medical technology company will post earnings of $3.34 per share for the quarter, down from their prior estimate of $3.35. The consensus estimate for Teleflex's current full-year earnings is $13.98 per share. Zacks Research also issued estimates for Teleflex's Q3 2025 earnings at $3.36 EPS, Q4 2025 earnings at $3.72 EPS, FY2025 earnings at $13.33 EPS, Q3 2026 earnings at $3.78 EPS, Q4 2026 earnings at $3.51 EPS and FY2026 earnings at $13.74 EPS.
Teleflex (NYSE:TFX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.88 by $0.03. The company had revenue of $700.67 million during the quarter, compared to analyst estimates of $699.37 million. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. The business's revenue was down 5.0% compared to the same quarter last year. During the same period in the prior year, the company earned $3.21 earnings per share.
TFX has been the topic of a number of other research reports. Piper Sandler reaffirmed a "neutral" rating and set a $140.00 price target (down previously from $255.00) on shares of Teleflex in a report on Friday, February 28th. Citizens Jmp cut Teleflex from an "outperform" rating to a "market perform" rating in a research report on Thursday, February 27th. Raymond James Financial lowered Teleflex from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company decreased their price target on Teleflex from $146.00 to $137.00 and set an "equal weight" rating for the company in a research note on Friday, May 2nd. Finally, Morgan Stanley cut their price objective on shares of Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research note on Monday, May 5th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Teleflex currently has a consensus rating of "Hold" and a consensus target price of $164.63.
View Our Latest Research Report on Teleflex
Teleflex Stock Performance
NYSE TFX traded up $0.30 during trading hours on Thursday, hitting $119.45. The company had a trading volume of 303,573 shares, compared to its average volume of 628,807. The company has a quick ratio of 1.32, a current ratio of 2.28 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $124.81 and a 200-day simple moving average of $148.76. The firm has a market cap of $5.28 billion, a P/E ratio of 37.68, a price-to-earnings-growth ratio of 1.88 and a beta of 1.10. Teleflex has a fifty-two week low of $115.94 and a fifty-two week high of $249.91.
Teleflex Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Monday, June 16th. Investors of record on Tuesday, May 20th were issued a $0.34 dividend. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.14%. Teleflex's payout ratio is currently 42.90%.
Institutional Investors Weigh In On Teleflex
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Strs Ohio purchased a new stake in shares of Teleflex during the first quarter valued at $3,040,000. IFM Investors Pty Ltd increased its stake in Teleflex by 7.8% in the 1st quarter. IFM Investors Pty Ltd now owns 8,311 shares of the medical technology company's stock worth $1,148,000 after purchasing an additional 602 shares in the last quarter. Jane Street Group LLC raised its holdings in Teleflex by 42.6% during the 1st quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company's stock worth $877,000 after buying an additional 1,895 shares during the period. Empowered Funds LLC lifted its stake in Teleflex by 15.8% during the first quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company's stock valued at $233,000 after buying an additional 230 shares in the last quarter. Finally, United Services Automobile Association acquired a new position in shares of Teleflex in the first quarter worth about $373,000. Institutional investors and hedge funds own 95.62% of the company's stock.
Teleflex Company Profile
(
Get Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Recommended Stories
Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
